MX349622B - Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. - Google Patents
Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.Info
- Publication number
- MX349622B MX349622B MX2013002679A MX2013002679A MX349622B MX 349622 B MX349622 B MX 349622B MX 2013002679 A MX2013002679 A MX 2013002679A MX 2013002679 A MX2013002679 A MX 2013002679A MX 349622 B MX349622 B MX 349622B
- Authority
- MX
- Mexico
- Prior art keywords
- activity
- therapeutic proteins
- conditionally active
- methods
- protein
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Abstract
La presente invención se refiere a un método in vitro para identificar/seleccionar una proteína terapéutica modificada que es una proteína antitumor que trata tumores y que tiene una mayor actividad en un microambiente de tumor en un sujeto comparado con un ambiente sin tumor en el sujeto, caracterizado porque comprende: i) probar la actividad de unión de una pluralidad de proteínas terapéuticas anti-tumor modificadas al objetivo de las proteínas terapéuticas anti-tumor bajo las condiciones a) y bajo las condiciones b), en donde: las proteínas terapéuticas anti-tumor son anticuerpos o porciones de unión al antígeno de los mismos; la condiciones en a) comprende pH bajo que está entre 5.8 y 6.8, y suero humano; las condiciones en b) comprende pH que está entre 7.2 y 7.8, y suero humano en la misma concentración que en a); la concentración de suero en ambas condiciones es la misma y es 15-35% en volumen; opcionalmente, las condiciones en a) en comparación con las condiciones en b) comprenden una o más propiedades adicionales a pH reducido seleccionadas de entre hipoxia, concentración de lactato incrementada y concentración de piruvato incrementada; el resto de las condiciones en a) y b) son las mismas; la actividad probada es la unión a la proteína objetivo de la proteína terapéutica; cada proteína terapéutica modificada contiene reemplazo de aminoácido, inserción y/o eliminación de un residuo o residuos de aminoácido comparados con la forma no modificada de la proteína terapéutica; y cada proteína modifica se prueba en cada una de las condiciones de a) y b); ii) comparar la actividad de unión de las proteínas terapéuticas modificadas en a) con la actividad de unión en b); y iii) seleccionar/identificar una proteína terapéutica modificada que tiene mayor actividad de unión para la proteína objetivo en a) comparada con b), de este modo identificando un anticuerpo terapéutico modificado o porción de unión al antígeno del mismo que es condicionalmente activo tal que tiene mayor actividad de unión en las condiciones de pH bajas de un microambiente de tumor comparado con las condiciones de pH de un ambiente sin tumor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40297910P | 2010-09-08 | 2010-09-08 | |
PCT/US2011/050891 WO2012033953A1 (en) | 2010-09-08 | 2011-09-08 | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013002679A MX2013002679A (es) | 2013-06-18 |
MX349622B true MX349622B (es) | 2017-08-07 |
Family
ID=44906358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013002679A MX349622B (es) | 2010-09-08 | 2011-09-08 | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
Country Status (9)
Country | Link |
---|---|
US (1) | US9683985B2 (es) |
EP (1) | EP2614086A1 (es) |
JP (2) | JP6121904B2 (es) |
KR (1) | KR20130096731A (es) |
CN (1) | CN103201293B (es) |
CA (1) | CA2810668A1 (es) |
IL (1) | IL224983A (es) |
MX (1) | MX349622B (es) |
WO (1) | WO2012033953A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
DE602004024041D1 (de) | 2003-03-05 | 2009-12-24 | Halozyme Inc | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
KR101463631B1 (ko) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | 항체의 혈중 동태를 제어하는 방법 |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
JP5649589B2 (ja) * | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用 |
CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
UA116528C2 (uk) | 2011-08-30 | 2018-04-10 | Астекс Фармасьютікалз, Інк. | Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
US20140170159A9 (en) * | 2012-03-08 | 2014-06-19 | Ge Wei | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
CN108503711A (zh) | 2012-04-30 | 2018-09-07 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
TWI617578B (zh) | 2012-05-30 | 2018-03-11 | Chugai Pharmaceutical Co Ltd | 標的組織專一的抗原結合分子 |
JP2013253842A (ja) * | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | pH依存的に標的分子に結合するペプチドのスクリーニング方法 |
KR102273985B1 (ko) | 2012-08-24 | 2021-07-06 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
CN105142677B (zh) | 2013-02-15 | 2019-08-30 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
EP2961388B1 (en) | 2013-03-01 | 2019-04-24 | Astex Pharmaceuticals, Inc. | Drug combinations |
CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
WO2015038984A2 (en) * | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
MX2016007312A (es) | 2013-12-04 | 2017-01-13 | Chugai Pharmaceutical Co Ltd | Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas. |
KR102246800B1 (ko) * | 2014-05-13 | 2021-04-30 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
AU2015267047A1 (en) * | 2014-05-27 | 2017-01-05 | Academia Sinica | Anti-CD20 glycoantibodies and uses thereof |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
US20170260261A1 (en) * | 2014-08-28 | 2017-09-14 | Bioatla, Llc | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells |
JP2017532019A (ja) | 2014-09-03 | 2017-11-02 | バイオアトラ、エルエルシー | 同じ真核細胞産生宿主における条件的活性型生物学的タンパク質の発見及び作製 |
AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
CN104531714A (zh) * | 2015-01-23 | 2015-04-22 | 香港中文大学深圳研究院 | 适用于植物表达体系的表达贝伐单抗的基因、重组载体及产贝伐单抗植物的构建方法及应用 |
SG10202108814VA (en) * | 2015-02-24 | 2021-09-29 | Bioatla Llc | Conditionally active biological proteins |
BR112017020948A2 (pt) | 2015-03-31 | 2018-07-10 | Ildong Pharm Co., Ltd. | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão |
US11400157B2 (en) | 2015-05-13 | 2022-08-02 | Chugai Seiyaku Kabushiki Kaisha | Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion |
EP3297658A1 (en) * | 2015-05-18 | 2018-03-28 | OncoQR ML GmbH | Her2/neu immunogenic composition |
KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
WO2017004538A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
WO2017078839A1 (en) * | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
CN116334113A (zh) * | 2016-01-08 | 2023-06-27 | 加利福尼亚大学董事会 | 有条件活性的异二聚体多肽及其使用方法 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3443012A4 (en) | 2016-04-15 | 2019-09-11 | Bioatla, LLC | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND ITS IMMUNOCONJUGATES AND USES THEREOF |
KR20230044567A (ko) | 2016-05-13 | 2023-04-04 | 바이오아트라, 인코퍼레이티드 | 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도 |
CN106222194A (zh) * | 2016-08-03 | 2016-12-14 | 深圳麦客思鱼生物科技发展有限公司 | 一种优化的植物源重组人源化贝伐单克隆抗体的制备方法及医药应用 |
WO2018044619A1 (en) * | 2016-08-31 | 2018-03-08 | Bioatla, Llc | Conditionally active polypeptides and methods of generating them |
WO2018132476A1 (en) | 2017-01-11 | 2018-07-19 | Bristol-Myers Squibb Company | Psgl-1 antagonists and uses thereof |
SG11201907848YA (en) * | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
WO2019025863A2 (en) | 2017-08-03 | 2019-02-07 | Otsuka Pharmaceutical Co., Ltd. | MEDICAMENT COMPOUND AND METHODS OF PURIFICATION |
CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
JP2021518133A (ja) * | 2018-03-21 | 2021-08-02 | ファイブ プライム セラピューティクス, インコーポレイテッド | 酸性pHでVISTAに結合する抗体 |
SG11202100102VA (en) * | 2018-07-11 | 2021-02-25 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
CN109001144A (zh) * | 2018-09-12 | 2018-12-14 | 上海海洋大学 | 基于中红外光谱快速鉴定和检测原肌球蛋白的方法 |
KR20230051630A (ko) * | 2018-10-31 | 2023-04-18 | 바이오아트라, 인코퍼레이티드 | 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도 |
CN114113569B (zh) * | 2021-11-25 | 2023-10-27 | 江苏科技大学 | 一种基于代谢组学技术建立BmNPV抗性品系家蚕筛选标准的方法 |
CN114483287A (zh) * | 2022-01-24 | 2022-05-13 | 浙江吉利控股集团有限公司 | 一种车用增氧装置及其控制方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4347935A (en) | 1979-05-16 | 1982-09-07 | The United States Of America As Represented By The United States Department Of Energy | Method and apparatus for electrostatically sorting biological cells |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US6969586B1 (en) | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5679640A (en) * | 1991-02-12 | 1997-10-21 | Cytel Corporation | Immunosuppressant peptides |
WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5545142A (en) | 1991-10-18 | 1996-08-13 | Ethicon, Inc. | Seal members for surgical trocars |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5483469A (en) | 1993-08-02 | 1996-01-09 | The Regents Of The University Of California | Multiple sort flow cytometer |
US5464581A (en) | 1993-08-02 | 1995-11-07 | The Regents Of The University Of California | Flow cytometer |
IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
US5643796A (en) | 1994-10-14 | 1997-07-01 | University Of Washington | System for sensing droplet formation time delay in a flow cytometer |
US5602039A (en) | 1994-10-14 | 1997-02-11 | The University Of Washington | Flow cytometer jet monitor system |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US6413544B1 (en) | 1996-08-19 | 2002-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
US20070009930A1 (en) | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6211477B1 (en) | 1998-02-26 | 2001-04-03 | Becton Dickinson And Company | Electrostatic deceleration system for flow cytometer |
US20090130718A1 (en) | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
US20020015970A1 (en) * | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
AU2003256266A1 (en) * | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
DE602004024041D1 (de) | 2003-03-05 | 2009-12-24 | Halozyme Inc | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen |
WO2005019255A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
EP1691763A4 (en) * | 2003-12-12 | 2008-03-12 | Genencor Int | CAB MOLECULES |
WO2005063817A2 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
US7442773B2 (en) * | 2004-01-23 | 2008-10-28 | The Board Of Trustees Of The University Of Illinois | Universal peptide-binding scaffolds and protein chips |
EP1722807A4 (en) | 2004-01-23 | 2010-09-15 | Cornell Res Foundation Inc | PROCESS FOR REDUCING OXIDATIVE DAMAGE |
CN103007279B (zh) | 2004-03-19 | 2017-01-11 | 英克隆有限责任公司 | 人抗表皮生长因子受体抗体 |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
NZ551627A (en) * | 2004-05-28 | 2010-02-26 | Agensys Inc | Antibodies and related molecules that bind to PSCA proteins |
JP2008510466A (ja) * | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
EP1820852A4 (en) * | 2004-11-19 | 2007-11-14 | Jms Co Ltd | HUMAN SERUM FOR CELL CULTURE |
EP2899277A1 (en) * | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
AU2007208340B2 (en) | 2006-01-23 | 2012-11-01 | Joseph P. Errico | Methods and compositions of targeted drug development |
CN101437833A (zh) | 2006-02-10 | 2009-05-20 | 辛辛那提大学 | 作为心脏功能调节剂的磷酸酶抑制剂蛋白-1 |
CA2638794A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
CA2644474A1 (en) * | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
EP1878747A1 (en) * | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
AU2007280398B2 (en) * | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
US20080131500A1 (en) | 2006-12-04 | 2008-06-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for rapid inactivation of proteins |
EP1975178A1 (en) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
PL2708558T3 (pl) * | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
JP2010068746A (ja) * | 2008-09-18 | 2010-04-02 | Chiba Univ | 抗腫瘍効果を有する化合物の同定方法 |
JP5649589B2 (ja) | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用 |
NO2406399T3 (es) | 2009-03-09 | 2018-07-14 | ||
DK3042957T3 (en) | 2009-07-17 | 2018-01-02 | Bioatla Llc | At the same time, integrated selection and development of human protein performance and expression in production hosts |
CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
US20140170159A9 (en) | 2012-03-08 | 2014-06-19 | Ge Wei | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
WO2015038984A2 (en) | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
-
2011
- 2011-09-08 CA CA2810668A patent/CA2810668A1/en not_active Abandoned
- 2011-09-08 MX MX2013002679A patent/MX349622B/es active IP Right Grant
- 2011-09-08 CN CN201180053564.6A patent/CN103201293B/zh not_active Expired - Fee Related
- 2011-09-08 KR KR1020137008951A patent/KR20130096731A/ko active IP Right Grant
- 2011-09-08 WO PCT/US2011/050891 patent/WO2012033953A1/en active Application Filing
- 2011-09-08 JP JP2013528300A patent/JP6121904B2/ja active Active
- 2011-09-08 EP EP11778725.9A patent/EP2614086A1/en not_active Withdrawn
- 2011-09-27 US US13/200,666 patent/US9683985B2/en not_active Expired - Fee Related
-
2013
- 2013-02-28 IL IL224983A patent/IL224983A/en not_active IP Right Cessation
-
2016
- 2016-03-09 JP JP2016046184A patent/JP2016166875A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN103201293B (zh) | 2016-04-27 |
JP2016166875A (ja) | 2016-09-15 |
CA2810668A1 (en) | 2012-03-15 |
CN103201293A (zh) | 2013-07-10 |
JP6121904B2 (ja) | 2017-04-26 |
US9683985B2 (en) | 2017-06-20 |
MX2013002679A (es) | 2013-06-18 |
IL224983A (en) | 2017-10-31 |
JP2013541940A (ja) | 2013-11-21 |
WO2012033953A1 (en) | 2012-03-15 |
KR20130096731A (ko) | 2013-08-30 |
US20120108455A1 (en) | 2012-05-03 |
EP2614086A1 (en) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX349622B (es) | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. | |
WO2011135194A3 (en) | Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes | |
CL2017000528A1 (es) | Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción | |
WO2009090553A3 (en) | Compositions and methods of detecting post-stop peptides | |
EA201491918A1 (ru) | Соединения - двойные агонисты gip-glp-1 и способы | |
WO2010088411A3 (en) | Conformationally dynamic peptides | |
WO2011047033A3 (en) | Biomarker for identification of melanoma tumor cells | |
NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
BR112012029281A2 (pt) | anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo | |
MX346923B (es) | Genes y proteinas para sintesis de alcanoil-coa. | |
MY162576A (en) | Modified factor ix polypeptides and uses thereof | |
EA201500080A1 (ru) | Способ in vitro диагностирования и мониторинга рака | |
WO2011156468A8 (en) | A method of predicting clinical outcomes for melanoma patients using circulating melanoma cells in blood | |
EP4234698A3 (en) | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies | |
TR201902439T4 (tr) | Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri . | |
PH12015502849B1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
MA44593A1 (fr) | Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations | |
CA2815892C (en) | Analytical methods and arrays for use in the same | |
CA2835730C (en) | Molecular markers in prostate cancer | |
MX2019004487A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
CY1118843T1 (el) | Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα | |
MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
GB2520889A (en) | Patient reported outcome instrument | |
WO2016205828A3 (en) | Role of citrullination in diagnosing diseases | |
EP4289970A3 (en) | Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |